BioSpace News Archive

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted inducement awards to two new non-executive employees.

Increase in geriatric population, rise in incidences of diabetes, obesity and chronic conditions, and technological advancements to deal with complex wounds drive the growth of the global advanced wound care market

The global smart syringe market is driven by rise in count of needle stick injuries, shift from conventional syringes to smart syringes, growth in awareness in emerging economies, and widespread adoption of safety syringes across all applications, especially in drug delivery.

Butterfly needle is a device utilized to draw blood from an access vein or deliver intravenous (IV) therapy through a vein.

Urethritis is an inflammation of the urethra. It shows numerous symptoms, such as pain during urination and an increased urge to urinate.

NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of Clinlogix, a leading, Philadelphia-based global clinical research organization.

On August 2, 2021, the US Food and Drug Administration approved the drug anifrolumab (Saphnelo) for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.

Scientists at Children’s Hospital of Philadelphia have identified two proteins that could be used for a potential vaccine against nontypeable Haemophilus influenzae.

Oncternal Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that management will participate in the BTIG Virtual Biotechnology Conference being held August 9-10, 2021.

Researchers led by City of Hope, a world-renowned research and treatment center for cancer, diabetes and other life-threatening diseases, have developed a powerful miniature brain platform to study the mechanistic causes of Alzheimer’s disease and to test dementia drugs in development, reports a new study published today in Advanced Science.